
Twist Bioscience (TWST) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
92.8M
Gross Profit
46.0M
49.60%
Operating Income
-41.6M
-44.79%
Net Income
-39.3M
-42.38%
EPS (Diluted)
$-0.66
Balance Sheet Metrics
Total Assets
595.6M
Total Liabilities
155.5M
Shareholders Equity
440.1M
Debt to Equity
0.35
Cash Flow Metrics
Operating Cash Flow
-17.4M
Free Cash Flow
-17.1M
Revenue & Profitability Trend
Twist Bioscience Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 313.0M | 245.1M | 203.6M | 132.3M | 90.1M |
Cost of Goods Sold | 179.6M | 155.4M | 119.3M | 80.6M | 61.4M |
Gross Profit | 133.3M | 89.7M | 84.2M | 51.7M | 28.7M |
Gross Margin % | 42.6% | 36.6% | 41.4% | 39.1% | 31.8% |
Operating Expenses | |||||
Research & Development | 90.9M | 106.9M | 120.3M | 69.1M | 43.0M |
Selling, General & Administrative | 218.4M | 189.7M | 212.9M | 135.9M | 103.3M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 309.2M | 296.6M | 333.3M | 205.0M | 146.3M |
Operating Income | -175.9M | -206.9M | -249.0M | -153.3M | -117.6M |
Operating Margin % | -56.2% | -84.4% | -122.3% | -115.8% | -130.5% |
Non-Operating Items | |||||
Interest Income | 15.3M | 14.4M | 3.1M | 435.0K | 1.5M |
Interest Expense | 29.0K | 5.0K | 80.0K | 367.0K | 787.0K |
Other Non-Operating Income | -47.6M | -10.9M | 17.8M | -836.0K | -22.7M |
Pre-tax Income | -208.2M | -203.5M | -228.3M | -154.0M | -139.5M |
Income Tax | 560.0K | 1.2M | -10.4M | -1.9M | 382.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -208.7M | -204.6M | -217.9M | -152.1M | -139.9M |
Net Margin % | -66.7% | -83.5% | -107.0% | -114.9% | -155.3% |
Key Metrics | |||||
EBITDA | -131.8M | -163.9M | -230.5M | -144.4M | -109.6M |
EPS (Basic) | $-3.60 | $-3.60 | $-4.04 | $-3.15 | $-3.57 |
EPS (Diluted) | $-3.60 | $-3.60 | $-4.04 | $-3.15 | $-3.57 |
Basic Shares Outstanding | 58016000 | 56885000 | 53885000 | 48251000 | 39190000 |
Diluted Shares Outstanding | 58016000 | 56885000 | 53885000 | 48251000 | 39190000 |
Income Statement Trend
Twist Bioscience Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 226.3M | 286.5M | 378.7M | 465.8M | 93.7M |
Short-term Investments | 50.1M | 49.9M | 126.3M | 12.0M | 196.3M |
Accounts Receivable | 34.9M | 44.1M | 40.3M | 26.5M | 25.8M |
Inventory | 24.1M | 32.1M | 39.3M | 31.8M | 12.3M |
Other Current Assets | 11.4M | 11.7M | 11.9M | 8.3M | 6.2M |
Total Current Assets | 346.8M | 424.3M | 596.5M | 546.5M | 334.9M |
Non-Current Assets | |||||
Property, Plant & Equipment | 158.4M | 176.0M | 137.2M | 110.0M | 71.0M |
Goodwill | 186.1M | 226.1M | 231.4M | 63.1M | 2.6M |
Intangible Assets | 14.5M | 54.5M | 59.7M | 18.3M | 307.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 5.9M | 8.5M | 5.0M | 6.2M | 3.4M |
Total Non-Current Assets | 267.5M | 352.1M | 364.9M | 155.6M | 64.0M |
Total Assets | 614.3M | 776.4M | 961.4M | 702.1M | 398.9M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.6M | 14.1M | 20.1M | 14.9M | 4.8M |
Short-term Debt | 14.8M | 14.9M | 13.6M | 9.8M | 9.7M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 961.0K | 430.0K | 12.6M | 6.1M | 1.9M |
Total Current Liabilities | 71.0M | 73.3M | 90.7M | 63.1M | 36.0M |
Non-Current Liabilities | |||||
Long-term Debt | 70.2M | 79.2M | 81.3M | 53.2M | 26.2M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 407.0K | 475.0K | 60.0K | 5.1M | 351.0K |
Total Non-Current Liabilities | 70.6M | 79.6M | 81.3M | 58.2M | 26.6M |
Total Liabilities | 141.6M | 153.0M | 172.0M | 121.3M | 62.6M |
Equity | |||||
Common Stock | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -1.2B | -1.0B | -828.4M | -610.6M | -458.5M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 472.7M | 623.4M | 789.4M | 580.8M | 336.3M |
Key Metrics | |||||
Total Debt | 85.0M | 94.1M | 94.9M | 62.9M | 36.0M |
Working Capital | 275.8M | 350.9M | 505.8M | 483.4M | 298.8M |
Balance Sheet Composition
Twist Bioscience Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -208.7M | -204.6M | -217.9M | -152.1M | -139.9M |
Depreciation & Amortization | 31.4M | 29.3M | 16.5M | 9.8M | 6.7M |
Stock-Based Compensation | 50.9M | 30.3M | 79.7M | 37.0M | 17.1M |
Working Capital Changes | 2.7M | 1.7M | -5.1M | -10.4M | -18.8M |
Operating Cash Flow | -121.7M | -146.6M | -119.5M | -113.3M | -135.7M |
Investing Activities | |||||
Capital Expenditures | -5.1M | -27.8M | -101.9M | -27.1M | -9.9M |
Acquisitions | 0 | 0 | -13.9M | -483.0K | 0 |
Investment Purchases | -51.9M | -76.3M | -217.6M | -58.8M | -202.9M |
Investment Sales | 53.9M | 154.7M | 100.5M | 242.5M | 98.1M |
Investing Cash Flow | -3.1M | 50.6M | -238.7M | 156.2M | -114.6M |
Financing Activities | |||||
Share Repurchases | -4.0M | -4.4M | -7.8M | -10.8M | -2.4M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | 0 | 0 | -1.6M | -3.3M | -3.3M |
Financing Cash Flow | -4.0M | -4.4M | 260.5M | 309.7M | 289.8M |
Free Cash Flow | -69.2M | -170.3M | -226.2M | -139.3M | -152.1M |
Net Change in Cash | -128.7M | -100.4M | -97.7M | 352.5M | 39.4M |
Cash Flow Trend
Twist Bioscience Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-7.35
Forward P/E
-11.53
Price to Book
3.53
Price to Sales
4.67
PEG Ratio
0.06
Profitability Ratios
Profit Margin
-23.52%
Operating Margin
-31.36%
Return on Equity
-17.58%
Return on Assets
-13.88%
Financial Health
Current Ratio
3.90
Debt to Equity
19.48
Beta
2.37
Per Share Data
EPS (TTM)
$-1.44
Book Value per Share
$7.95
Revenue per Share
$6.10
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
twst | 1.7B | -7.35 | 3.53 | -17.58% | -23.52% | 19.48 |
Thermo Fisher | 184.1B | 28.17 | 3.64 | 13.42% | 15.24% | 69.62 |
Danaher | 146.0B | 43.29 | 2.79 | 6.68% | 14.21% | 35.45 |
Neogen | 1.2B | 865.00 | 0.59 | -41.88% | -122.06% | 44.14 |
Grail | 1.1B | -0.49 | 0.49 | -17.68% | -62.12% | 2.69 |
Opko Health | 1.1B | -17.13 | 0.82 | -13.16% | -26.68% | 30.51 |
Financial data is updated regularly. All figures are in the company's reporting currency.